文献速递血栓与止血

两种互补自动化快速检测联合诊断肝素诱导性血小板减少症

Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT).
PubMed 文献 · J Thromb Haemost · 2020-04-27

该研究利用两个队列(n=430和n=147)及678份连续样本,评估LIA与CLIA联合检测对HIT的诊断效能。联合检测灵敏度约99%,与EIA相似;LIA/CLIA 6分评分越高,存在血小板活化抗体的概率越大,评分≥4分时概率约98%。

要点

  • LIA与CLIA联合检测诊断HIT灵敏度约99%,与EIA相似。
  • LIA/CLIA评分≥4分时,SRA或PF4增强SRA检出血小板活化抗体的概率约98%。
  • 评分越高,血小板活化抗体存在的可能性逐步增大。

核心结论

  • 联合LIA/CLIA检测优化了诊断灵敏度,且检测反应性越高,检出血小板活化抗体的概率越大,当两种自动化检测均呈中等或强阳性时可达98%。

研究设计与样本

  • 利用HIT观察性试验(n=430,推导队列)和147例连续HIT患者(补充推导队列)的LIA/CLIA联合结果确定操作特征。
  • 另评估678份连续送检HIT检测的样本(复制队列)。

主要发现

  • 联合LIA/CLIA检测诊断灵敏度约99%,与EIA相似。
  • 采用6分制解读LIA/CLIA结果,评分越高,存在血小板活化抗体的可能性逐步增大(半定量反应性)。
  • LIA/CLIA评分≥4分时,SRA或PF4增强SRA检出血小板活化抗体的概率约98%。

关键数值与推荐

  • LIA/CLIA反应性评分:阴性<1.00 U/mL(0分),弱阳性1.00-4.99 U/mL(1分),中等阳性5.00-15.99 U/mL(2分),强阳性≥16.00 U/mL(3分)。
  • LIA/CLIA联合最高6分,评分≥4分预测血小板活化抗体(SRA或PF4增强SRA)概率约98%。

临床怎么用

  • 临床可采用LIA与CLIA联合检测辅助诊断HIT,高评分(≥4分)提示血小板活化抗体存在概率高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIT diagnosis typically uses complementary diagnostic assays (eg, a PF4-dependent enzyme-immunoassay [EIA] and a platelet activation assay such as the serotonin-release assay [SRA]). OBJECTIVES: To determine whether the combination of two automated assays-a latex immunoturbidimetric assay (LIA) that evaluates competitive inhibition of a HIT-like monoclonal antibody and a chemiluminescence immunoassay (CLIA) for detecting anti-PF4/heparin IgG-optimizes diagnostic sensitivity while also yielding good specificity, particularly at high assay reactivities. PATIENTS/METHODS: We determined operating characteristics using combined LIA/CLIA results from a HIT observational trial (n = 430; derivation cohort) and 147 consecutive patients with HIT (n = 147; supplementary derivation cohort). We also evaluated 678 consecutive samples referred for HIT testing (replication cohort). LIA/CLIA reactivities were scored individually as "negative" (<1.00 U/mL, 0 points), "weak" (1.00-4.99 U/mL, 1 point), "moderate" (5.00-15.99 U/mL, 2 points) and "strong" (≥16.00 U/mL, 3 points), thus contributing up to 6 points (maximum) when LIA/CLIA results were combined. We also examined whether higher LIA/CLIA scores predicted presence of platelet-activating antibodies by conventional and modified (PF4- or PF4/heparin-enhanced) SRA. RESULTS: Combined LIA/CLIA testing yielded high diagnostic sensitivity (~99%) similar to EIA. Interpretation of LIA/CLIA results using the 6-point scale indicated progressively greater likelihood for the presence of platelet-activating antibodies with increasing scores (semi-quantitative reactivity). A LIA/CLIA score ≥ 4 points predicted the presence of platelet-activating antibodies by SRA or PF4-enhanced SRA with high probability (~98%). CONCLUSION: Combined LIA/CLIA testing optimizes diagnostic sensitivity, with progressively greater probability of detecting platelet-activating antibodies with higher assay reactivity that reaches 98% when both automated assays yield moderate or strong results.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Warkentin TE, Sheppard JI, Smith JW, et al. Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT). J Thromb Haemost. 2020. PMID: 32167669. doi:10.1111/jth.14794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。